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Summary
In group sequential clinical trials, it is necessary to estimate the amount of information
present at interim analysis times relative to the amount of information that would be present
at the final analysis. If only one measurement is made per individual, this is often the ratio
of sample sizes available at the interim and final analyses. However, as discussed by Wu
and Lan (1992), when the statistic of interest is a change over time, as with longitudinal
data, such an approach overstates the information. In this paper, we discuss other problems
that can result in overestimating the information, such as heteroscedasticity and correlated
observations. We demonstrate that when using an inefficient estimator on unbalanced data,
the true information growth can be nonmonotonic across interim analyses.
Key Words: Unbalanced data; Inefficient estimators.
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1

Introduction

In many group sequential clinical trials, repeated measurements are made on continuous outcomes for each individual over a specified follow up time period. Such longitudinal measures
may be used to evaluate possible treatment effects, such as time averaged measurement (area
under the curve), rate of change (slope), or difference between initial and final values, any of
which can be taken as specific cases of a weighted area under the curve approach (Kittelson
et al., 2005). For illustrative purposes, we consider when the outcome of interest is the rate
of change over time, such as when monitoring tumor growth, CD4+ cell counts, or cognitive
decline in Alzheimer’s Disease.
For ethical and financial reasons, it is usually necessary to perform interim analyses of
data from clinical trials before all study data have been collected. In order to maintain
the type I error rate, several methods are commonly used, including the stopping rules
proposed by Pocock (1977), O’Brien and Fleming (1979), Whitehead and Stratton (1983),
and the error spending function approach of Lan and DeMets (1983). However, in order
to be implemented in a flexible manner, all methods require an estimate of the amount of
statistical information present at each analysis time. This estimated information can then
be used to generate appropriate stopping boundaries at any particular analysis time.
In order to make correct statistical inference in a study, it is important that the true
information growth be accurately modeled. Failure to do so may lead to grossly incorrect
type I and type II errors. In settings where only one outcome measurement is obtained
on each individual, the proportionate information at a particular analysis time is often
calculated as a ratio of the number of measurements at the analysis time to the total expected
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number of measurements; in the case of survival data, the current information is the number
of events observed relative to the total expected. However, even when the proportionate
information can be correctly computed, problems can arise due to the need to estimate
nuisance parameters affecting the variability of measures of treatment effect. Burington
and Emerson (2003) noted that imprecision of the estimated nuisance parameters can lead
to error spending boundaries that do not reflect the true known proportionate information
available at each analysis, while boundaries constrained on other scales will not necessarily
adhere to the desired boundary shape function. Several authors have further conjectured
that the imprecision inherent in estimating within group variances or baseline event rates
at the earliest of interim analyses might lead to a spurious appearance of nonmonotonic
information growth during the monitoring of a study (Scharfstein et al., 1997; Burington
and Emerson, 2003) Such situations are likely rare in practice due to the relatively large
increments of information typically accrued between successive analyses: the monotonic
increase in available data overwhelms the potential nonmonotonicity in the estimates of the
nuisance parameters across the analyses.
Further complications arise when treatment effects are measured by a contrast across
study time in a longitudinal clinical trial. In that setting, the number of available measurements relative to the final expected number of measurements overestimates the current statistical information, even when the true effect is linear in time and the data are homoscedastic
(Wu and Lan, 1992). This argues that a naive approach to estimating information based
solely on sample size is problematic. However, a larger concern would be settings in which
the true information growth might be nonmonotonic in that the variability of the estimated
treatment effect was higher at a later interim analysis than it was at one conducted earlier.
Were that to occur, standard stopping boundaries for group sequential trials would not be
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appropriate because the assumption of independent increments is violated.
Previous authors (Scharfstein et al., 1997; Jennison and Turnbull, 1997) showed that using
the efficient estimator leads to an independent increment structure in a group sequential
trial and that the information growth therefore must be monotonic. They note that using
an inefficient estimator does not preclude independent increments, but conjecture that it
may lead to nonmonotonicity in some circumstances. However, Scharfstein et al. (1997)
speculate that such nonmonotonicities are rare and only arise in practice due to estimation
of the information growth as discussed above. In this manuscript, we expand on their work
by presenting situations in which the information growth is nonmonotonic in truth.
For this paper, we restrict attention to the case where the statistic of interest is of
a linear contrast over time. First, we consider the case of independent longitudinal data
and investigate the consequences of inaccurately estimating the information growth in a
clinical trial. We then consider the case of correlated longitudinal data and discuss issues
regarding information growth when using generalized estimating equations (GEE) in this
setting including scenarios leading to nonmonotonic information growth.

2

Notation and Group Sequential Methods

In a group sequential trial testing a null hypothesis of H0 : θ = θ0 against a one-sided
alternative, a stopping rule is defined over a schedule of analyses, occurring at times t1 , ...,
tJ , where J is the maximal number of analyses. These stopping rules are typically defined
in terms of a continuation set, Cj = (aj , bj ] ∪ [cj , dj ), with −∞ ≤ aj ≤ bj ≤ cj ≤ dj ≤ ∞. If
the test statistic, Sj is contained in the continuation set, Cj , the trial continues to the next
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analysis time, tj+1 . By defining CJ as the empty set the trial is assured of having no more
than J analyses. These continuation sets are determined in part by the amount of statistical
information at each analysis time, relative to the amount of information expected at the end
of the trial. This will be referred to as the information growth over the course of the study,
which we compute as

1/V ar(θ̂j )
1/V ar(θ̂J )

and denote by πj for analysis time tj .

Using the unified family approach (Kittelson and Emerson, 1999), the boundaries are
determined by the following formula, with parameters A, P, and R specified to determine
the behavior of the boundaries at possible early termination points (the ∗ denotes a, b, c, or
d).

ν∗ (π; A, P, R, G) = (A∗ + πj−P∗ (1 − πj )R∗ )G∗

(1)

The parameter G is found by iterative search to obtain desired operating characteristics.
These operating characteristics usually focus on the type I and type II statistical errors as
well as some measure of “conservatism” at the early analyses. Specifically this conservatism
is often considered as testing for the treatment effect of interest with a smaller type I error
rate, such as 0.005 before continuing the study. We note that this conservatism could also
be thought of as increasing the size of the effect for which efficacy would be declared, i.e.
this early test has a boundary that would lead to a 95% confidence interval suggestive of a
larger effect than would the 95% confidence interval at the end of the study. In any case,
it is necessary to weigh the scientific and clinical implications of the stopping rules when
determining boundaries. If a trial were to stop early, additional information that might be of
interest, such as being able to characterize long-term effects or gaining increased knowledge
of potential safety issues, would not be obtained.
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In the unified family approach above, A∗ = 0, P∗ ≥ 0, R∗ = 0 corresponds to the Wang
and Tsiatis (1987) one-parameter boundaries. In this parameterization, increasing values
of P∗ lead to decreased early conservatism. In the special case P∗ = 0.5 these boundaries
correspond to the Pocock (1977) boundaries, if P∗ = 0, the boundaries correspond to those
of O’Brien and Fleming (1979), and if P∗ = ∞, there is no early stopping.
In most trials where one outcome measurement is made on each individual accrued,
πj =

Nj
,
NJ

the ratio of the number of measurements at the time tj to the number that would

be available at the end of the trial. If the primary outcome is survival, then usually πj =

Dj
,
DJ

the ratio of the number of events observed by time tj to the number expected at the end of
the study. However, neither of these holds in the longitudinal case, which is the setting for
this manuscript.

3

Information Growth with a Linear Model

We consider the case where the treatment effect of interest is the change over time, for
example the difference in rates of tumor growth between a placebo and a treatment group.
For now, we focus on the case where there is no correlation in the data. One example in
which this might occur is if the population being studied over time was a group of rats with
the same treatment and same starting point for the disease and then at each time point
a single rat was selected for analysis. Independent data are obtained when the analysis at
each time point cannot be performed on the same rat over time. In the case of the tumor
growth example, measuring the tumor at a particular time point requires an autopsy and
thus each rat is only measured once. In the models below, we use x to denote the time from
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randomization and we reserve reference to time to denote analysis times (tj ) in the study.
For simplicity we restrict attention to a one-sample model; in a randomized controlled trial
both groups would be analyzed similarly.
Let the outcome measurement Yik be the observation for cluster i at some time xk from
randomization. We assume measurements are known to be independent across clusters.
The total number of measurements expected to be observed over the course of the study is
thus I ∗ K where I denotes the number of clusters observed and K denotes the number of
observations that will be made on each cluster over the duration of the study. In the example
of tumor growth in rats, a cluster would be a single rat. Each observation Yik would be made
when one of the rats was sacrificed to measure the tumor growth. In other studies, a cluster
could simply be one participant measured at K time points from the time that participant
was randomized.
In this model the regression formula is:

E(Y |X = x) = β0 + β1 ∗ x.

(2)

The parameter of interest β1 is the change in the outcome (Y ) over time from randomization
(x). Consider initially the case when the true treatment effect corresponds exactly to the
analysis method used; data are homoscedastic and the treatment effect (slope) is constant
over the length of the follow up time. In this setting the standard error of β̂1 can be
calculated exactly. For a particular analysis time tj , the standard error depends on the
number of measurements observed by that point in the study, the variance of the outcome at
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any fixed point in time, and the variance of the predictor variable (time from randomization):

V arj (β̂1 ) =

2
σy|x

nj ∗ V arj (x)

.

(3)

1/V ar(θ̂ )

Thus, the estimate of the information growth ( 1/V ar(θ̂ j ) ) that relies only on the fraction
J

N
( NJj )

of the total measurements made does not account for the fact that the variance of the

time from randomization (V ar(x)) is also increasing with study time (V arj (x) ≤ V arJ (x)).
Therefore, simply using the proportion of expected total measurements as a surrogate for
the information growth will overestimate the true information growth.
Figure 1 shows the fraction of information present as a function of study time for different
accrual periods. Here there are 10 observed time points (i.e., k=1,...,10) with measurements
taken at baseline and at each month thereafter, (i.e., x1 = 0, x2 = 1, ..., x10 = 9). The
accrual periods vary from nearly instantaneous (0.1 month accrual) to long relative to the
length of follow up (30 months). In all cases, using the proportion of expected measurements
as a surrogate for the amount of information (dashed line) overestimates the actual amount of
information present. Qualitatively, this overestimation is most problematic when the accrual
time is short relative to the length of follow up. If the accrual period is long relative to the
length of follow up on a cluster, the true information curve is close to the information curve
approximated by the relative number of measurements. Intuitively, this is reasonable. In an
extreme case where all measurements for the study are made on the last recruited cluster
prior to accrual of a new cluster, the increase in information would almost entirely be due to
the next measurement obtained, rather than increasing variability of the x measurements.
In this situation estimating the information growth using the model-based standard errors
yields correct estimates of the information at various analysis times; however simply using
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Figure 1: Plots showing the true information growth (solid line) relative to the information
growth that would be estimated from the fraction of the total number of measurements
(dashed line). In all cases, estimating the IG by the number of measurements overestimates
the true information.
the number of measurements made does not. Using the incorrect estimates of the information
to form boundaries can result in incorrect type I errors. This will be discussed in greater
detail in the next section.
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4

Impact of Incorrect Information Growth Estimates

4.1

Incorrect Type I Error

If the relative amount of information is overestimated at an interim analysis time tj , the type
I error will be inflated. This is a result of overstating the precision with which our parameter
of interest is known, thus setting the stopping boundaries too narrow for the analysis at time
tj . Therefore, under the null, the estimate at this time point is outside of these boundaries
more often than expected and the type I error is inflated.
To illustrate, consider 10 measurements taken at times 0-9, with an accrual period of 2
months (i.e., the calendar time for all subjects to complete the study is 11 months). Assume
that four analyses are planned to be evenly spaced in calendar time (i.e., every 2.75 months),
and analyses are to be conducted using either the stopping boundary shape described by
Pocock (1977) or O’Brien and Fleming (1979). We consider single boundary stopping rules
that allow for early stopping only under the alternative, and two boundary stopping rules
that allow for early stopping for futility as well. The designs are constructed to maintain
a fixed two-sided 0.05 type I error rate and to have 97.5% power for a specific alternative
when using the true information growth.
Table 1 shows the dramatic increase in type I error when using the naive information
growth estimates in this setting. The boundaries are constructed to maintain a fixed 0.05
error rate, yet the single boundary type I error is 0.34 using the Pocock boundary and
0.21 using an O’Brien-Fleming boundary. For two boundary designs, the type I errors are
0.31 and 0.20, respectively. In this case, the estimated information is greater than the
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Table 1: Stopping probabilities (SP) under the null and the alternative with 97.5% power
using Pocock and O’Brien-Fleming (OBF) stopping boundaries.

Single
Calendar
Pocock
Time
Naive IG SPnull SPalt
0.25
0.225
0.274 0.452
0.50
0.50
0.056 0.274
0.75
0.775
0.011 0.181
1.00
1.00
0.002 0.072
Overall power 0.34 0.978
Single
Calendar
Pocock
Time
True IG SPnull SPalt
0.25
0.015
0.007 0.027
0.50
0.14
0.007 0.187
0.75
0.48
0.006 0.521
1.00
1.00
0.005 0.266
Overall power 0.025 0.975

Naive IG
Boundary
Two Boundary
OBF
Pocock
OBF
SPnull
SPalt
SPnull SPalt SPnull
SPalt
0.138
0.270
0.277 0.499 0.141
0.274
0.046
0.308
0.028 0.163 0.040
0.271
0.018
0.298
0.003 0.042 0.012
0.206
0.008
0.107 <0.001 0.003 0.003
0.047
0.21
0.983
0.31
0.71
0.20
0.80
True IG
Boundary
Two Boundary
OBF
Pocock
OBF
SPnull
SPalt
SPnull SPalt SPnull
SPalt
<0.001 <0.001 0.007 0.032 <0.001 <0.001
<0.001 <0.001 0.007 0.244 <0.001 <0.001
0.002
0.456
0.006 0.557 0.002
0.462
0.023
0.519
0.004 0.142 0.023
0.513
0.025
0.975
0.025 0.975 0.025
0.975

true information, which causes the boundaries at interim analyses to be too narrow. This
results in some null trials being declared effective when they would not have been if stopping
boundaries constructed with the correct information had been used. This can be seen by
noting the difference in early stopping probabilities at each analysis under the naive estimates
of the information and under the true information when the null hypothesis is true. The
inflation of the type I errors is slightly less for designs with with both efficacy and futility
boundaries, as some trials are stopped prematurely early for futility, thus preventing these
trials from contributing to the type I error.
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4.2

Loss of Power

When using a single efficacy stopping boundary, there is a very slight increase in power under
the alternative because the interim boundaries are closer to the null and these make it more
likely for trials to be declared effective. When using both efficacy and futility boundaries,
in addition to the inflation of the type I error, there is also a loss of power due to the
overestimated information. Table 1 also shows that for the alternative with 97.5% power
under the true information growth, the power is only 71% using Pocock boundaries and
80% using O’Brien-Fleming. This is again due to the overestimated information causing the
interim boundaries to be too narrow; in this case the boundary for futility causes some trials
that would eventually reject the null to be stopped early for futility.

4.3

Nonmonotonic Boundaries

If the estimated information growth is nonmonotonic, the stopping boundaries can be nonmonotonic as well. In extreme cases, an estimated or true nonmonotonicity in the information growth can lead to boundaries that preclude stopping at the interim analysis entirely.
This will be further explored in the next two sections that deal with heteroscedasticity and
correlated observations, respectively.

5

Information Growth and Heteroscedastic Data

We next examine the case in which the measurements are heteroscedastic, such as if the
measurements were becoming increasingly variable over time, but that the analysis model
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(erroneously) presumes homoscedasticity. This might occur if there were rigid entry criteria
for the study at baseline, such as a systolic blood pressure measurement between 130 and
140 and we were interested in measuring it over time. In one such case with increasing
variability, the data might be generated from a model such as the one below where x again
is the time from randomization.

Yix ∼ (µx , σ 2 (x + 1)γ )

(4)

As a consequence of this increasing variability, both the true information growth and the
analysis model-based estimate of the information growth can be nonmonotonic (figure 2). If
the effect is truly linear but later measurements are much more variable than early ones, the
later measurements will detract from the precision with which we can estimate the slope.
However, even if this extreme case is true, there may be more pressing reasons to continue
with the later measurements, such as providing evidence that the linear trend exists (or does
not exist) over a longer range of time.
In figure 2 the accrual pattern and measurement schedule match those from the previous section (2 month accrual, measurements at baseline and months 1-9 thereafter). The
heteroscedasticity was generated as in equation (4), with σ 2 = 1 and γ = 2. The analysis model-based estimates of the information growth from ordinary least squares regression
assuming constant variance are different from the true information growth obtained by simulation. For the true information growth, when the first measurement that is more variable
occurs, the information may in fact drop. Then, as more measurements that are more variable are accrued during this interval, the information increases, as would be expected with
increasing the number of observations. The initial drop in information is in part attributable
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Figure 2: Plot illustrating information growth when the data are truly heteroscedastic. The
solid line represents the true, nonmonotonic information growth, simulated empirically. The
dashed line represents the model-based estimates of the information growth. The above was
simulated assuming σ = 1 and γ = 2 in a model like that of equation (4).
to the amount of influence the first points can have on the estimated slope. As the first more
variable measurements are of high influence, the actual variability of the β̂1 parameter is
increased when these first points are added. When balance is achieved, such as at the end of
a study with no dropout and no missing measurements, heteroscedascitiy is less of a concern,
because no point is overly influential.
In contrast, the analysis model-based estimates of the information growth are constrained
by the assumption of constant variance. Thus, when adding points that are more variable,
the estimate of the constant variance is only slightly altered by a few measurements with
more variability. The estimate of the variance increases as more measurements with increased
variability are added, so the estimate of the constant variance is highest only after all the
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additional measurements have been taken. This is usually offset by gains in the number of
measurements leading to more typical behavior of the information growth curve. However, it
can lead to dramatic cases in which the estimated information is lowest after all of the more
variable measurements have been accrued if the later measurements are much more variable
than the earlier ones (e.g., if γ is extremely large in the above data generation model).

5.1

Consequences of Incorrect Information Growth Estimates

As before, overestimating the information growth at a particular analysis point (such as using
the model-based estimate of the information growth in this setting) can lead to incorrect type
I error. In the extreme cases where the true information growth is nonmonotonic, and the
estimated information at a planned analysis time is less than the information at a previous
analysis time (i.e., πj > πk ; j < k), one obvious solution is to not do an analysis at this time
point. Certainly, the standard software available for conducting group sequential analyses
cannot be used in such a circumstance, and in the case of possible nonmonotonicity due to
heteroscedasticity, it is expected that the information will improve by the end of the trial
(when balance is again obtained). Therefore, if extreme heteroscedascity is a concern, it
would make sense to plan for interim analyses at times where as much balance as possible
will be attained.

6

Information Growth with Correlated Observations

We now turn attention to the case where multiple longitudinal measurements are correlated,
such as when measuring tumor growth in an individual over time. One approach to such
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data is to use generalized estimating equations (GEE) to estimate the treatment effect over
time (Liang and Zeger, 1986).
When GEE is used, a “working” covariance matrix structure is specified to use as weights
in the estimation of the parameters. Common choices for the specification of the working
covariance matrix W (ρ) include independence, exchangeable (Wij = ρ, i 6= j), and auto regressive with order one (AR(1); Wij = ρ|i−j| ). A completely unstructured working covariance
matrix can also be used; in this case all off diagonal elements of the matrix are estimated
separately. If the working covariance matrix is not independence, an iterative process is used
to solve for W (ρ̂) and β̂. In most cases, the estimates of β̂ will be unbiased regardless of the
choice of working covariance, however in certain circumstances with time-varying covariates,
the estimates may be biased if working independence is not used (Pepe and Anderson, 1994).
When the working covariance matrix is close to the truth, the estimates will be most efficient
(Wang and Carey, 2003). However, using simple forms of the working covariance matrix may
be justified in many situations due to a lack of knowledge of the true correlation structure, a
desire to be robust to possible misspecification of the correlation or the linear model, or the
convenience in estimation when a simple structure of the working covariance matrix is used.
In GEE, the regression parameter estimates are given by:

β̂ = (X T W −1 X)−1 X T W −1 Y.

(5)

The estimated standard errors then account for the correlation between observations made
on the same cluster, where V is the true correlation between clusters (usually estimated with

http://biostats.bepress.com/uwbiostat/paper358

Estimates of Information Growth in Longitudinal Clinical Trials - 17

the empirical version in GEE):

V ar(β̂) = (X T W −1 X)−1 X T W −1 V̂ W −1 X(X T W −1 X)−1

(6)

If the correlation structure is known, then letting W = V makes the GEE and GLS estimates
equivalent, and this estimator is the best linear unbiased estimator by the Gauss-Markov
theorem. If the true correlation structure is unknown but the form of the working covariance
matrix is correctly specified such that W →p V , then this estimator will be asymptotically
efficient. If the working covariance matrix is independence, then the point estimates for β̂
match those that would be obtained using ordinary least squares regression (OLS) exactly.
If not, point estimates for β̂ will be like those that would have been obtained using GLS
with a similar correlation structure.
As noted previously, the amount of additional information obtained between interim
analysis times during a longitudinal clinical trial depends on several factors, including the
number of additional measurements and the increased variability in the predictor variable
(time since randomization). With correlated measurements the amount of additional information will also depend on the degree of correlation between the new measurements and
the previous measurements. In the extreme case of nearly perfectly correlated data and
no new individuals (clusters), there is almost no new statistical information obtained, even
as additional measurements are collected, because the new measurements are almost completely determined by knowledge of the high correlation and the assumed linear model. If
the correlation between the new measurements and the old ones is not correctly accounted
for in the estimate of β̂, problems can arise, specifically nonmonotonic information growth
when the addition of measurements results in increased variability of the point estimate.
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Using GEE to estimate the longitudinal treatment effect can lead to nonmonotonic information growth curves. This can occur even when everything is correctly specified: the linear
contrast is exactly correct, the data are homoscedastic, the clusters are correctly identified,
and the “robust” standard error estimates are derived using the sandwich estimator. One
situation in which this can occur is when the design is unbalanced. For instance, at an
interim analysis during the conduct of a clinical trial, some individuals may have had three
total measurements while other individuals have only had two. Previous authors have noted
that using an independence working covariance matrix can lead to relative inefficiency in this
setting compared to using a working covariance matrix that matches the form of the true
data (Wang and Carey, 2003) . We note that using an incorrectly specified working covariance matrix (and thus inefficient weights) can lead to absolute inefficiencies as well. Such
absolute inefficiency can lead to nonmonotonic information growth curves: In certain situations there is more statistical information when everyone has just two measurements than
when everyone has two measurements and a handful of individuals have three measurements.
Intuition might suggest that the reason for this absolute inefficiency is due to the weighting on the measurements when determining the estimate of β̂. For example, we noted
previously that if an independence working covariance matrix is used, the estimate of β̂1 will
match exactly the estimate that would have been obtained through OLS regression ignoring
the correlation within an individual. When all individuals have the same number of measurements at the same time points from randomization, all subjects are weighted equally
and this does not generally result in a great loss of efficiency. However, this is not true
when a few individuals have more measurements than the others. Compared to the case of
all independent measurements, the line fit with just two observations on each subject when
those observations are highly correlated is much less variable (there is a gain in information
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due to the positive correlation within an individual). If only a handful of these highly correlated subjects have measurements at a more extreme time point, these subjects have greater
influence on the slope (as if they were new, independent measurements), and the variability
of the slope increases due to chance selection of different measurements over hypothetical
repeated experiments. This can actually increase the true variability of the slope, unless
the correlation with other measurements is properly accounted for by downweighting the
additional observations (using the working covariance matrix) relative to the weights that
would be used in OLS regression.
Figure 3 shows the true information growth curves under situations where the true effect
is linear, the data are homoscedastic, and the correlation within individuals is high. To be
consistent with our prior setting, 10 measurements were made on each individual, one at
baseline, and one at each of nine follow up times. For an example of high within individual
correlation, we chose an AR(1) structure with ρ = 0.95. In an attempt to make the exchangeable correlation structure as equivalent as possible, ρ for the exchangeable case was
chosen such that the average correlation between all pairs of measurements on an individual
at the end of the study would be equal to that in the AR(1) structure (ρ = 0.8338). Finally,
to ensure comparability, the number of individuals in the AR(1) case was increased such
that the final amount of statistical information was equivalent between the AR(1) and exchangeable cases (2170 and 500 individuals, respectively). Four working covariance matrices
were used in each simulation: independence, exchangeable, AR(1), and unstructured. The
plots demonstrate the nonmonotonic behavior using the independence working covariance
matrix in this setting. The scaled plots show the relative loss of efficiency compared to
using the correctly specified form of the working covariance matrix. In this setting, using
an exchangeable working covariance matrix appears to be most desirable; it does lose some
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Figure 3: Plot illustrating information growth over time using GEE when the data are truly
linear. The true correlation structure is either exchangeable or AR(1) and the plots show
the information growth using each of four working covariance matrices. The scaled graphs
show the true information growth relative to the amount of information when the working
covariance matrix is exactly specified.
efficiency relative to using AR(1) when the truth is AR(1) (relative efficiency = 89%), but
does not become nonmonotonic. In contrast, when the true data are exchangeable, using a
working AR(1) structure leads to a dramatic drop in efficiency (relative efficiency = 50%).
Some authors have suggested the use of an “unstructured” working covariance matrix
with GEE to provide nearly efficient estimation without pre-specifying the form of the working covariance (Gange and DeMets, 1996). Others have suggested that using a working
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covariance matrix with consistently estimated parameters (even if misspecified) will lead to
nearly independent increments (Lee et al., 1996). Using an “unstructured” working covariance matrix does lead to nearly efficient estimation when the design is balanced (when all
subjects have equal numbers of measurements), however in preliminary investigations, it
performs poorly when the design is markedly unbalanced, yielding results similar to using
an independence working covariance matrix (figure 3). These simulations were done using
the geepack package in R (Yan and Fine, 2004). When the design is unbalanced, some
estimated parameters in the working covariance structure appear to be quite variable due to
only a few observations contributing to those estimates. For this reason, using the unstructured working covariance can lead to many of the same problems as using the independence
working covariance, which suggests that in most circumstances the use of the exchangeable
working covariance matrix would be preferred. In addition, in a small number of simulations
(approximately 3%) using an unstructured working correlation matrix meant that the GEE
estimates did not converge. These cases were excluded from our estimates, and hence the
graphs underestimate the true magnitude of the problem.
As might be expected, the degree of correlation within measurements on the same individual affects the true information growth when using an independence working covariance
matrix (figure 4). When the true data are exchangeable with low correlation (ρ = 0.3) and
the same study design as before (2 month accrual, 10 measurements per individual), the
information growth is nearly the same between the exchangeable and independence working
covariance matrices (figure 4A). As the correlation increases, using working independence
becomes less efficient at interim points in the trial and can lead to nonmonotonic information
growth (figure 4: A-C).
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Figure 4: Plots illustrating the effect of the within individual correlation and the accrual
pattern on the information growth over time using GEE. In all cases, the data are truly linear
the covariance within individuals has an exchangeable structure, and 10 measurements are
made on each individual (at baseline and months 1-9). For plots A-C, accrual was fixed at
2 months and for plots D-F the correlation was fixed at ρ = 0.8338.
When the design is completely balanced (as might occur at the end of a study with no
dropout), the estimates using independence and exchangeable working covariance matrices
are the same. Such balance may also be achieved during a study if the accrual period is
shorter than the time between consecutive measurements on an individual. In our example
where individuals are measured every month, this would occur if everyone were accrued
within one month (e.g., every individual has a first measurement before anyone has a second
as in figure 4D). However, when the design is far from balanced (as might occur during a long
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accrual period), working independence will be noticeably less efficient than exchangeable at
interim points in the study when the true data are exchangeable (e.g. figure 4F).
A long accrual period when using an independence working covariance matrix leads
to relative inefficiency, but does not tend to lead to noticeable nonmonotonic information
growth. Nonmonotonicity is most pronounced when the accrual period is short relative to the
follow up on each individual and if the correlation within an individual is high (figure 4D).
Consider a case of high within subject correlation (ρ = 0.8338) and short accrual (so that all
individuals have two measurements before anyone has a third). In this situation, the amount
of statistical information decreases when the first individual gets at third measurement, and
continues to decrease until slightly more than 10% of the study population has a third
measurement. The amount of information present when everyone had two measurements
but no one had a third is not surpassed until more than 50% of the new third measurements
are obtained. This becomes even more striking as the study continues. When everyone has
nine measurements but no one yet has ten, the amount of statistical information decreases
when the first person gets a tenth measurement and continues to decrease until approximately
30% have a tenth measurement. The amount of information is not greater than the amount
when no one had a tenth until 70% have a tenth measurement.

6.1

Consequences of Nonmonotonic Information Growth

GEE can have nonmonotonic information growth in truth, but the information growth is
well estimated in these cases by the so-called “robust” standard errors computed using the
sandwich estimator. However, some of the problems of nonmonotonic information growth
discussed in the previous section remain. Specifically, analyses should be planned to take
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place at points in the study where the design will have as much balance as possible to
avoid situations where nonmonotonic information growth may potentially occur. Using an
exchangeable working covariance will also be helpful in avoiding potentially nonmonotonic
information growth while preserving most of the efficiency even if the true correlation structure is AR(1).

7

Conclusions/Discussion

There are different considerations for the planning of analyses in a group sequential clinical
trial than for planning a trial with only one analysis time. In particular, for a group sequential
clinical trial the rules determining the schedule of analyses must be completely pre-specified
and the behavior and estimation of the information growth over the course of the study must
be considered. We have demonstrated that poorly estimated information growth can lead
to substantial inflation of type I error and loss of power, and we have also shown that when
using GEE in certain circumstances the true information growth may be nonmonotonic.
If nonmonotonicity were to occur in a trial, it could be ignored, by refusing to proceed
with the scheduled interim analysis. It could also be avoided by moving the interim analysis
time to the point in the trial where the maximum information thus far in the trial was
achieved. However, in both of these scenarios the planned interim analysis is not being
performed. In many cases, we may not truly believe that the data are exactly linear, and
may be interested in a linear contrast over time. If the planned analysis is not done due
to nonmonotonic information growth, the linear contrast intended to be estimated at that
time point is not assessed, and any ethical and efficiency concerns that motivated the use of
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a stopping rule are not being addressed. Furthermore, the nonmontonic information growth
is clear evidence of a violation of the independent increments assumption, and application
of stopping boundaries derived under that assumption may be problematic.
It should be noted that the pathological behavior of the information growth was observed in extreme cases with unusually high correlation between observations. However, it
is nonetheless important to maintain the correct type I error by using the correct information growth. In the case of GEE, using the exchangeable working covariance will tend to
avoid the possibility of nonmonotonic information growth and would seem to preserve most
of the efficiency, even when the true correlation structure is not exchangeable. This paper
has focused on the effects of poorly estimated covariance when the mean model is exactly
correct; future work will investigate the effects of model misspecification on the estimated
information growth in these longitudinal settings.
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